In the pathogenesis of rheumatoid arthritis and primary biliary cirrhosis, the tumor necrosis factor-alpha has an important role. We describe the case of a 61-years-old woman with rheumatoid arthritis and primary biliary cirrhosis treated with anti-tumor necrosis factor-alpha agents. During treatment with golimumab, we found an improvement in liver function, but rheumatoid arthritis remained poorly controlled. When etanercept was started, the disease activity of rheumatoid arthritis was significantly improved and liver function was also improved despite the appearance of Pityriasis Rosea during etanercept. This case shows that etanercept therapy maintained liver enzymes within normal limits in PBC and controlled arthritis with a 10-month follow-up but the maintenance of this treatment was limited by the appearance of the pityriasis rosea.